Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Intradigm has announced that the US Patent and Trademark Office has allowed US patent application, which generally claims methods of enhancing the RNA silencing activity of an RNAi agent in a mammalian or plant cell.
Subscribe to our email newsletter
The allowed subject matter is not only focused on claims to siRNAs but also includes specific coverage for micro RNAs (miRNAs), miRNA precursors, primary miRNA transcripts and short hairpin RNA (shRNA).
The allowed application, based on the seminal research by Philip Zamore, is one of several applications disclosing certain efficacy-enhancing structural elements of RNAis that Intradigm exclusively licensed from the University of Massachusetts Medical School.
Mohammad Azab, president and CEO of Intradigm, said: “The US Patent and Trademark Office’s allowance of these patent claims represents an important milestone for Intradigm as it will allow us to incorporate novel enhanced RNAi sequences into our proprietary RNAi delivery systems to create potent and efficacious therapeutics.”